Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Alternative Dosing of Exemestane in Postmenopausal Women With Stage 0-II ER-Positive Breast Cancer: A Randomized Presurgical Trial

NCT02598557 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02598557
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02598557 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Alternative Dosing of Exemestane in Postmenopausal Women With Stage 0-II ER-Positive Breast Cancer: A Randomized Presurgical Trial
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
December 6, 2016
Completion date
February 2, 2023
Enrollment
180 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

stage 0 breast cancer ajcc v6 and v7, stage i breast cancer ajcc v7, stage ia breast cancer ajcc v7, stage ib breast cancer ajcc v7, stage ii breast cancer ajcc v6 and v7, stage iia breast cancer ajcc v6 and v7, stage iib breast cancer ajcc v6 and v7